Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Glioblastoma stem cells after treatment with HLM006474, S3I-201 or their combination.

ABSTRACT: Glioblastoma stem cells after treatment with HLM006474, S3I-201 or their combination.

PROVIDER: PRJNA784515 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17064165_1.fastq.gz	Fastqsanger.gz
	SRR17064165_2.fastq.gz	Fastqsanger.gz
	SRR17064166_1.fastq.gz	Fastqsanger.gz
	SRR17064166_2.fastq.gz	Fastqsanger.gz
	SRR17064167_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 30

Similar Datasets

Glioblastoma stem cells after treatment with HLM006474, S3I-201 or their combination.

Project description:Malignant gliomas, including glioblastoma (GBM), are uniformly lethal with inferior prognosis and lack of effective treatment. Although the H2AZ2 variant histone is overexpressed in diverse cancer types where it promotes cancer cell proliferation, there are no H2AZ2 inhibitors to-date for clinical intervention. Here, we explored approaches to pharmacologically target the H2AZ2-dependent pathways in GBM.

2022-01-15 | GSE189781 | GEO

Abernathy2016 - glioblastoma treatment

Project description:The paper describes a model of glioblastoma. Created by COPASI 4.25 (Build 207) This model is described in the article: Modeling the Treatment of Glioblastoma Multiforme and Cancer Stem Cells with Ordinary Differential Equations Kristen Abernathy and Jeremy Burke BMC Computational and Mathematical Methods in Medicine Volume 2016, Article ID 1239861, 11 pages Abstract: Despite improvements in cancer therapy and treatments, tumor recurrence is a common event in cancer patients. One explanation of recurrence is that cancer therapy focuses on treatment of tumor cells and does not eradicate cancer stem cells (CSCs). CSCs are postulated to behave similar to normal stem cells in that their role is to maintain homeostasis. That is, when the population of tumor cells is reduced or depleted by treatment, CSCs will repopulate the tumor, causing recurrence. In this paper, we study the application of the CSC Hypothesis to the treatment of glioblastoma multiforme by immunotherapy. We extend the work of Kogan et al. (2008) to incorporate the dynamics of CSCs, prove the existence of a recurrence state, and provide an analysis of possible cancerous states and their dependence on treatment levels. To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models . To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

2024-09-02 | BIOMD0000000757 | BioModels

Glioblastoma stem cells after treatment with anti-E2F, anti-STAT3 or their combination.

Project description:Glioblastoma stem cells after treatment with anti-E2F, anti-STAT3 or their combination.

| PRJNA736665 | ENA

Response to the combination of farnesyltransferase inhibitors and gamma-secretase inhibitors in glioblastoma stem cells

Project description:Notch-targeted gamma-secretase inhibitors (GSIs) exhibited limited efficacy in glioblastoma patients. We identified that farnesyltransferase inhibitors (FTIs) increased sensitivity to GSIs in glioblastoma stem cells. To interrogate the mechanisms mediating the interaction between these two classes of compounds, we studied the impact on gene expression profiles by the combination of tipifarnib (FTI) and RO4929097 (GSI). We found that this combination treatment significantly suppressed genes implicated cell cycle progression. Real-time PCR validated the activities of tipifarnib to modulate expression of cell cycle regulators. We also showed that RO4929097 sensitized glioblastoma stem cells to compounds targeting some of these cell cycle regulators, such as AURKB and CDK4/6. These results suggest that regulation of cell cycle progression partially mediates the ability of FTIs to sensitize glioblastoma stem cells to GSIs.

2017-10-11 | GSE104783 | GEO

Glioblastoma stem cells after treatment with sulconazole.

Project description:Glioblastoma stem cells after treatment with sulconazole.

| PRJNA628508 | ENA

RNA-seq of glioblastoma stem cells with CCL21 treatment

Project description:RNA-seq of glioblastoma stem cells with CCL21 treatment

2023-08-04 | GSE178337 | GEO

mRNA expression signatures of human glioblastoma stem cell like cells after treatment with FG-3019, irradiation and FG-3019 + irradiation

Project description:To investigate effects on mRNA expression through treatment with FG-3019, irradiation and their combination to gain mechanistic hypotheses on the effects of these treatments on glioblastoma stem cell like cells which have been observed in vitro and in vivo. mRNA expression was measured 6 h after treatment with FG-3019, irradiation and their combination. 3 biological replicates were analyzed for each treatment condition (control, FG-3019, irratiation and FG-3019+irradiation)

2014-08-30 | E-GEOD-60921 | biostudies-arrayexpress

4SC-201 (Resminostat) in Advanced Colorectal Carcinoma

Project description:The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of 4SC-201 (Resminostat) in combination with FOLFIRI and whether 4SC-201 (Resminostat) is effective and safe in combination FOLFIRI versus FOLFIRI alone in the treatment of advanced colorectal carcinoma.

| 2100868 | ecrin-mdr-crc

RNA-seq of glioblastoma stem cells with CCL21 treatment

Project description:RNA-seq of glioblastoma stem cells with CCL21 treatment

| PRJNA738513 | ENA

mRNA expression signatures of human glioblastoma stem cell like cells after treatment with FG-3019, irradiation and FG-3019 + irradiation

2014-08-30 | GSE60921 | GEO